Skip to main content
. 2022 May 25;14(11):2613. doi: 10.3390/cancers14112613

Figure 1.

Figure 1

Evolution of identification of actionable alterations and appropriate targeted therapies in the standard of care in advanced non-small-cell lung cancer (NSCLC). (A) The discovery of oncogenic drivers in NSCLC led to the development of more personalised medicine and improved response rate and overall survival over the years. (B) Increasing number of FDA-approved drugs for treatment of oncogene-addicted NSCLC.